0001861657 2026-01-01 2026-03-31 0001861657 2026-05-11 0001861657 2026-03-31 0001861657 2025-12-31 0001861657 2025-01-01 2025-03-31 0001861657 us-gaap:CommonStockMember 2024-12-31 0001861657 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001861657 us-gaap:RetainedEarningsMember 2024-12-31 0001861657 us-gaap:TreasuryStockCommonMember 2024-12-31 0001861657 2024-12-31 0001861657 us-gaap:CommonStockMember 2025-12-31 0001861657 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001861657 us-gaap:RetainedEarningsMember 2025-12-31 0001861657 us-gaap:TreasuryStockCommonMember 2025-12-31 0001861657 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001861657 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001861657 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001861657 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0001861657 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001861657 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001861657 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001861657 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-31 0001861657 us-gaap:CommonStockMember 2025-03-31 0001861657 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001861657 us-gaap:RetainedEarningsMember 2025-03-31 0001861657 us-gaap:TreasuryStockCommonMember 2025-03-31 0001861657 2025-03-31 0001861657 us-gaap:CommonStockMember 2026-03-31 0001861657 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001861657 us-gaap:RetainedEarningsMember 2026-03-31 0001861657 us-gaap:TreasuryStockCommonMember 2026-03-31 0001861657 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001861657 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001861657 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001861657 us-gaap:WarrantMember 2025-01-01 2025-03-31 0001861657 CNTN:CashSecuritiesPurchaseAgreementsMember 2025-11-03 2025-11-03 0001861657 CNTN:CashSecuritiesPurchaseAgreementsMember 2025-11-03 0001861657 CNTN:PrefundedWarrantsMember CNTN:CashSecuritiesPurchaseAgreementsMember 2025-11-03 0001861657 CNTN:PrefundedWarrantsMember CNTN:CryptocurrencyOfferingMember 2025-11-03 0001861657 CNTN:PrefundedWarrantsMember CNTN:CryptocurrencyOfferingMember 2025-11-03 2025-11-03 0001861657 CNTN:CashOfferingAndCryptocurrencyOfferingMember 2025-11-03 2025-11-03 0001861657 CNTN:CashOfferingAndCryptocurrencyOfferingMember 2025-11-03 0001861657 CNTN:StrategicAdvisorWarrantsMember CNTN:CashSecuritiesPurchaseAgreementsAndCrytocurrencySecuritiesPurchaseAgreementsMember 2025-11-03 0001861657 srt:MaximumMember CNTN:TwoThousandTwentyFiveATMAgreementMember 2025-11-06 2025-11-06 0001861657 CNTN:TwoThousandTwentyFiveATMAgreementMember 2025-01-01 2025-12-31 0001861657 CNTN:TwoThousandTwentyFiveATMAgreementMember 2025-12-31 0001861657 us-gaap:CommonStockMember 2026-01-21 2026-01-21 0001861657 us-gaap:CommonStockMember 2026-01-21 0001861657 CNTN:PrefundedWarrantsMember 2026-01-21 0001861657 2026-01-21 0001861657 2026-01-21 2026-01-21 0001861657 CNTN:MarchTwoThousandTwentySixATMAgreementMember 2026-03-03 2026-03-03 0001861657 CNTN:TwoThousandTwentyFiveATMAgreementMember 2026-01-01 2026-03-31 0001861657 CNTN:TwoThousandTwentyFiveATMAgreementMember 2026-03-31 0001861657 CNTN:TwoThousandSeventeenStockIncentivePlanMember 2026-03-31 0001861657 CNTN:TwoThousandSeventeenStockIncentivePlanMember 2026-01-01 2026-03-31 0001861657 CNTN:TwoThousandSeventeenStockIncentivePlanMember 2025-12-31 0001861657 CNTN:TwoThousandNineteenStockIncentivePlanMember 2026-01-01 2026-03-31 0001861657 CNTN:TwoThousandNineteenStockIncentivePlanMember 2026-03-31 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2025-01-01 2025-01-01 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2025-06-10 2025-06-10 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2025-10-09 2025-10-09 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2025-10-09 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2026-01-29 2026-01-29 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2026-01-30 2026-01-30 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2026-01-01 2026-03-31 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2025-01-01 2025-12-31 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2026-03-31 0001861657 CNTN:StrategicAdvisorWarrantsMember 2026-01-01 2026-03-31 0001861657 CNTN:StrategicAdvisorWarrantsMember 2026-03-31 0001861657 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0001861657 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001861657 us-gaap:RestrictedStockUnitsRSUMember 2026-03-31 0001861657 2025-01-01 2025-12-31 0001861657 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001861657 us-gaap:EmployeeStockOptionMember 2025-03-31 0001861657 CNTN:ResearchAndDevelopmentExpensesMember 2026-01-01 2026-03-31 0001861657 CNTN:ResearchAndDevelopmentExpensesMember 2025-01-01 2025-03-31 0001861657 CNTN:GeneralAndAdministrativeExpensesMember 2026-01-01 2026-03-31 0001861657 CNTN:GeneralAndAdministrativeExpensesMember 2025-01-01 2025-03-31 0001861657 CNTN:WarrantsOneMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsOneMember 2026-03-31 0001861657 CNTN:WarrantsTwoMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsTwoMember 2026-03-31 0001861657 CNTN:WarrantsThreeMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsThreeMember 2026-03-31 0001861657 CNTN:WarrantsFourMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsFourMember 2026-03-31 0001861657 CNTN:WarrantsFiveMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsFiveMember 2026-03-31 0001861657 CNTN:WarrantsSixMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsSixMember 2026-03-31 0001861657 CNTN:WarrantsSevenMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsSevenMember 2026-03-31 0001861657 CNTN:WarrantsEightMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsEightMember 2026-03-31 0001861657 CNTN:WarrantsNineMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsNineMember 2026-03-31 0001861657 CNTN:WarrantsTenMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsTenMember 2026-03-31 0001861657 CNTN:WarrantsElevenMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsElevenMember 2026-03-31 0001861657 CNTN:WarrantsTwelveMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsTwelveMember 2026-03-31 0001861657 CNTN:WarrantsThirteenMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsThirteenMember 2026-03-31 0001861657 CNTN:WarrantsFourteenMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsFourteenMember 2026-03-31 0001861657 CNTN:WarrantsFifteenMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsFifteenMember 2026-03-31 0001861657 CNTN:WarrantsSixteenMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsSixteenMember 2026-03-31 0001861657 CNTN:WarrantsSeventeenMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsSeventeenMember 2026-03-31 0001861657 CNTN:WarrantsEighteenMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsEighteenMember 2026-03-31 0001861657 CNTN:WarrantsNineteenMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsNineteenMember 2026-03-31 0001861657 CNTN:WarrantsTwentyMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsTwentyMember 2026-03-31 0001861657 CNTN:WarrantsTwentyOneMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsTwentyOneMember 2026-03-31 0001861657 CNTN:WarrantsTwentyTwoMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsTwentyTwoMember 2026-03-31 0001861657 CNTN:WarrantsTwentyThreeMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsTwentyThreeMember 2026-03-31 0001861657 CNTN:WarrantsTwentyFourMember 2026-01-01 2026-03-31 0001861657 CNTN:WarrantsTwentyFourMember 2026-03-31 0001861657 2023-01-01 2023-01-31 0001861657 CNTN:MinotaurAgreementMember 2026-01-01 2026-03-31 0001861657 CNTN:MinotaurAgreementMember 2025-01-01 2025-03-31 0001861657 CNTN:AppliedBiomedicalScienceInstituteMember 2023-07-27 2023-07-27 0001861657 CNTN:ABSIMember 2023-07-04 2023-07-05 0001861657 srt:MaximumMember CNTN:AppliedBiomedicalScienceInstituteMember 2023-07-04 2023-07-05 0001861657 2024-03-11 2024-03-11 0001861657 CNTN:AppliedBiomedicalScienceInstituteMember 2026-01-01 2026-03-31 0001861657 CNTN:AppliedBiomedicalScienceInstituteMember 2025-01-01 2025-03-31 0001861657 CNTN:IntractPatentLicenseAgreementMember 2023-11-03 2023-11-03 0001861657 srt:MaximumMember 2023-11-03 2023-11-03 0001861657 CNTN:AviorPatentLicenseAgreementMember 2026-01-01 2026-03-31 0001861657 CNTN:AviorPatentLicenseAgreementMember 2025-01-01 2025-03-31 0001861657 CNTN:EnkefalosLicenseAgreementMember 2024-06-17 2024-06-17 0001861657 CNTN:EnkefalosLicenseAgreementMember 2026-01-01 2026-03-31 0001861657 CNTN:EnkefalosLicenseAgreementMember 2025-01-01 2025-03-31 0001861657 CNTN:IntractPatentLicenseAgreementMember 2024-09-11 2024-09-11 0001861657 CNTN:IntractPatentLicenseAgreementMember 2025-01-01 2025-06-30 0001861657 CNTN:IntractPatentLicenseAgreementMember 2026-01-01 2026-03-31 0001861657 CNTN:IntractPatentLicenseAgreementMember 2025-01-01 2025-03-31 0001861657 CNTN:PresidentStreetGlobalMember us-gaap:RelatedPartyMember 2025-12-31 0001861657 CNTN:DigitalAssetTreasuryMember 2026-03-31 0001861657 CNTN:DigitalAssetTreasuryMember 2025-12-31 0001861657 CNTN:ClinicalStageBioTechnologyMember 2026-03-31 0001861657 CNTN:ClinicalStageBioTechnologyMember 2025-12-31 0001861657 CNTN:DigitalAssetTreasuryMember 2026-01-01 2026-03-31 0001861657 CNTN:DigitalAssetTreasuryMember 2025-01-01 2025-03-31 0001861657 CNTN:ClinicalStageBioTechnologyMember 2026-01-01 2026-03-31 0001861657 CNTN:ClinicalStageBioTechnologyMember 2025-01-01 2025-03-31 0001861657 us-gaap:SubsequentEventMember CNTN:TwoThousandTwentyFiveATMAgreementMember 2026-04-01 2026-05-11 iso4217:USD shares iso4217:USD shares pure CNTN:Integer CNTN:Segment false Q1 --12-31 0001861657

10-Q true 2026-03-31 2026 false 001-41210 CANTON STRATEGIC HOLDINGS, INC. DE 84-2642541 34 Shrewsbury Ave. Suite 1C Red Bank NJ 07701 (732) 889-3111 Not applicable Common stock, $0.0001 par value CNTN NASDAQ Yes Yes Non-accelerated Filer true true false false 69804880

41532140

17032748

1553110

353318

43085250

17386066

541569363

501760369

584654613

519146435

402311

1090274

739033

2196090

1141344

3286364

113713951

117934191

114855295

121220555

0.0001

10000000

0.0001

1000000000

56656517

37112466

56656271

37112220

5665

3711

590024159

470809478

-120160541

-72817344

246

69965

469799318

397925880

584654613

519146435

267823

594070

36600488

1952599

36868311

2546669

-36868311

-2546669

8471

318178

13436

-15013304

-14695126

4965

-51563437

-2541704

-4220240

-47343197

-2541704

-0.23

-0.99

207705905

2572715

1973999

198

38278503

-36901094

246

-69965

1307642

100000 10 -10 200212 200212

35000

-3

-2541704

219179

2108999

211

38697881

-39442798

246

-69965

-814671

37112466

3711

470809478

-72817344

246

-69965

397925880

2195772

1800000 180 52698348 52698528

7921179

792

34992622

34993414

9590012 959 -959 5680 1 -1 64579 6 94705 94711

162601

-16

-829775

-47343197

32259757

56656517

5665

590024159

-120160541

246

-69965

469799318

-47343197

-2541704

-15013304

-4220240

32259757

219179

1199792

423103

-687963

63003

-1457057

-6376

-7635188

-2689001

54822298

-54822298

54894300 35526308

94711

3558441

308924 60325

43031

86956878

205568

24499392

-2483433

17032748

3559361

41532140

1075928

8471

314485

200212

Note 1 – Description of Business Nature of Operations Canton Strategic Holdings, Inc., formerly known as Tharimmune, Inc. (“Canton Strategic,” “Tharimmune,” or the “Company”) was incorporated on March 28, 2017, as a Delaware C-corporation. At March 31, 2026, Canton Strategic had one wholly-owned subsidiary: Gravitas Life Sciences, Inc. (“Gravitas”), formerly known as Hillstream Oncology, Inc. Digital Asset Treasury Strategy On November 6, 2025, in connection with a private placement with certain accredited investors (see Note 4 to the consolidated financial statements), Canton Strategic Holdings, Inc. announced the launch of a digital asset treasury strategy, pursuant to which the Company became the first publicly traded company to leverage Canton Coin (“CC”) and support the Canton Network to advance institutional blockchain adoption and the digitization of financial markets. Under the new treasury policy and strategy, the principal holding in our treasury reserve on the balance sheet will be allocated to digital assets, primarily CC by applying a public-market treasury model to an asset that is believed to be earlier in its lifecycle, structurally reflexive, and underexposed as compared to other digital assets. The planned approach involves acquiring CC directly through operation as a Super Validator and run additional Validators on the Canton Network as a mechanism to obtain additional CC. In addition to operating the Company’s previous clinical-stage biotechnology business, management will focus its resources on the new treasury policy and a significant portion of the balance sheet will be allocated to holding CC digital assets in the digital asset treasury. On February 18, 2026, in conjunction with this strategy, the Company changed its name from Tharimmune, Inc. to Canton Strategic Holdings, Inc, pursuant to an amended and restated Certificate of Incorporation filed with the Delaware Secretary of State. Clinical-stage Biotechnology Business As a subsidiary of Canton Strategic, Gravitas is a clinical-stage biotechnology company developing therapeutic candidates for unmet needs. GV104, its’ lead clinical stage development candidate obtained via a Patent License Agreement with Avior Bio, LLC. (“the Avior Agreement”), is being developed for a proposed indication of temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders entering an area contaminated with high-potency opioids (“PrHPO”). The FDA provided feedback that will allow Gravitas to submit a 505(b)(2) New Drug Application (“NDA”) for GV104 and confirmed that it does not believe any additional clinical trials will be required to define the prophylactic dosing window prior to NDA submission for this indication. Gravitas is progressing its Chemistry, Manufacturing, and Controls (“CMC”) plan to meet the stringent requirements for filing an NDA. Gravitas’ second program, GV023, obtained via a Patent License Agreement with Intract Pharma Limited (the “Intract Agreement”), is an oral anti-Tumor Necrosis Factor-alpha (TNF-α) monoclonal antibody with the known active biologic, infliximab. Infliximab is a purified, recombinant DNA-derived chimeric IgG monoclonal antibody protein that contains both murine and human components that inhibit TNF-α. Under the terms of the Intract Agreement, Gravitas licensed global development and commercialization rights (outside of South Korea) to Intract’s Soteria® and Phloral® delivery platform along with an existing supply agreement for infliximab to be used in the oral product development program. Gravitas has also developed preclinical candidates targeting validated high value immuno-oncology (“IO”) targets including human epidermal growth factor (“EGF”) receptor 2 (“HER2”), human EGF receptor 3 (“HER3”) and programmed cell death protein 1 (“PD-1”).

Note 2 – Summary of Significant Accounting Policies Basis of Presentation These accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company operates in two reportable segments. Principles of Consolidation The consolidated financial statements include the accounts of Canton Strategic and its wholly-owned subsidiary, Gravitas. All significant intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Areas of the consolidated financial statements where estimates may have the most significant effect include fair value of cryptocurrency, research and development expense recognition, valuation of common shares and share-based compensation, allowances of deferred tax assets, valuation of debt related instruments, and cash flow assumptions regarding going concern considerations. Although management believes the estimates that have been used are reasonable, actual results could vary from the estimates that were used. Segment Reporting As a result of the Company’s adopting a digital asset treasury strategy, the Company now has two reportable segments: digital assets and clinical stage bio-technology. The digital assets segment operates a CC-centric digital asset treasury strategy. The clinical stage bio-technology segment develops therapeutic candidates for rare, inflammatory and oncologic conditions. See Note 9 for additional information on the Company’s segments. Concentration of Credit Risk The Company maintains cash balances with various financial institutions. Account balances at these institutions are insured by the Federal Deposit Insurance Corporation up to $250,000 per depositor. At various times during the year, bank account balances may have been in excess of federally insured limits. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents, if any, are stated at cost and consist primarily of money market accounts. Digital Assets The Company accounts for its digital assets, which are comprised of CC, as intangible assets in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 350-60, Intangibles—Goodwill and Other-Crypto Assets. The Company’s digital assets are initially recorded at cost and subsequently measured at fair value with the gain or loss associated with remeasurement of the digital assets recognized in net income (loss) during each reporting period. Upon disposal of a digital asset (e.g., by sale, exchange or transfer), the Company derecognizes the asset and recognizes a realized gain or loss in net income, calculated as the difference between the consideration received and the asset’s carrying amount. The fair value of the Company’s digital assets is determined based on quoted prices in its principal market at the time of measurement. The Company determines its principal market as the market that it has access to and has the greatest volume and level of orderly transactions in accordance with FASB ASC 820, Fair Value Measurement. The Company tracks the cost of its digital assets using the first-in-first-out (FIFO) method. Research and Development Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials, and manufacture drug supplies and materials. These expenses also include costs associated with license fee arrangements and collaboration agreements, including milestone payments and ongoing license fees, which are also expensed as incurred. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by third parties, patient enrollment in clinical trials, administrative costs incurred by third parties, and other indicators of the services completed. Stock-Based Compensation The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees, and directors as an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock-based award. The fair value of common stock issued pursuant to termination agreements as well as restricted stock or restricted stock units is generally measured as the grant-date price of the Company’s common stock. The fair value of each option grant to employees, non-employees, and directors is estimated as of the date of grant using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on the straight-line basis over the requisite service period of the awards, which is generally the vesting period. Prior to January 12, 2022, the Company was a private company and the Company’s common stock has only been publicly traded since that date. As a result, the Company has limited company-specific historical and implied volatility information. Therefore, it has estimated its expected stock volatility based on the historical data of a publicly traded set of peer companies. The expected term of stock options granted was between five and seven years. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant for time periods approximately equal to the expected term of the award. Fair Value Measurements The Company applies FASB ASC Topic 820, Fair Value Measurement (“ASC 820”), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances. The carrying value of the Company’s cash, prepaid expenses, accounts payable, and accrued expenses approximate fair value because of the short-term maturity of these financial instruments. The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 Inputs: Observable inputs such as quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 Inputs: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for assets or liabilities recently traded in active markets, with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals, as well as quoted prices for identical or similar assets or liabilities in markets that are not active. </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 Inputs: Unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities, that reflect the reporting entity’s own assumptions.</td></tr> </table> The Company applies ASC 820 in the valuation of CC held by the Company for financial statement purposes. The fair value of CC uses Level 1 inputs to reflect the price that would be received for CC in a current sale, which assumes an orderly transaction between market participants on the measurement date in CC’s “principal market,” or in the absence of a principal market, the most advantageous market. Market participants are defined as buyers and sellers in the principal or most advantageous market that are independent, knowledgeable, and willing and able to transact. The Company determines its principal market (or in the absence of a principal market, the most advantageous market) on a periodic basis to determine which market is its principal market for the purpose of calculating fair value for the creation of quarterly and annual financial statements. Issuer-specific events, market trends, bid/ask quotes of brokers and information providers and other data may be reviewed in the course of making a good faith determination of the digital asset’s fair value. Income Taxes The Company accounts for income taxes using the asset-and-liability method in accordance with FASB ASC Topic 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred income taxes are recognized for the tax effect of temporary differences between the financial statement carrying amount of assets and liabilities and the amounts used for income tax purposes and for certain changes in valuation allowances. Valuation allowances are recorded to reduce certain deferred tax assets when, in management’s estimation, it is more-likely-than-not that a tax benefit will not be realized. A full valuation allowance has been recognized for all periods since it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in future periods. The Company follows the guidance in FASB ASC Subtopic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely-than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more-likely-than-not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. At March 31, 2026 and December 31, 2025, the Company had no unrecognized uncertain income tax positions, and therefore no amounts have been recognized in the consolidated financial statements. Patent Costs Costs associated with the submission of patent applications, including milestone fees and success fees, are expensed as incurred given the uncertainty of the future economic benefits of the patents. Patent and patent related legal and administrative costs are included in general and administrative expenses in the accompanying consolidated statements of operations. Net Loss per Share The Company reports loss per share in accordance with FASB ASC Subtopic 260-10, Earnings Per Share, which provides for calculation of basic and diluted earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives effect to common stock equivalents; however, potential common shares are excluded if their effect is anti-dilutive. <p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zkAoNkaN8Sh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">Potentially dilutive securities not included in the computation of loss per share for the three months ended March 31, 2026 and 2025 are as follows: Schedule of Potentially Dilutive Equity Shares not Included in Computation of EPS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260101__20260331_z7BsEytA0qNj" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250101__20250331_zGPTO9xMkS0g" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended March 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z7d55QDU2rK2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Outstanding options to purchase shares of common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">656,163</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">242,788</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_ziMkqISUvQai" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants to purchase shares of common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13,239,833</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">928,676</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zwEqvZsFAXF8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">13,895,996</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,171,464</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Recent Accounting Pronouncements In December 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-08, Intangibles - Goodwill and Other - Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets. This standard requires certain crypto assets meeting defined criteria to be measured at fair value each reporting period with changes in fair value recognized in net income, presented separately from other intangible assets and accompanied by enhanced disclosures. This standard was effective for fiscal years beginning after December 15,2024, with early adoption permitted. The Company adopted this standard during the year ended December 31, 2025 in conjunction with its new treasury strategy. Since the Company held no digital assets until November 2025, the adoption of this standard had no impact to prior reported financial statements and no cumulative adjustment to retained earnings was required or recorded. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires expanded segment reporting and disclosure and is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted this guidance in the year ended December 31, 2025 as it previously did not have multiple reportable segments. This standard did not have a material impact on its financial statements other than enhanced disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which expands income tax footnote disclosure requirements, including rate reconciliation and income taxes paid disclosures. The standard is effective for fiscal years beginning after December 15, 2024. The ASU affects disclosure only and does not impact the recognition or measurement of income taxes under ASC 740. Accordingly, adoption of ASU 2023-09 had no impact on the Company’s income tax provision. In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses and in January 2025, the FASB issued ASU No. 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, which clarified the effective date of ASU 2024-03 for non-calendar year-end companies. ASU 2024-03 will require the Company to disclose the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization, as applicable, included in certain expense captions in the consolidated statements of operations, as well as qualitatively describe remaining amounts included in those captions. ASU 2024-03 will also require the Company to disclose both the amount and the Company’s definition of selling expenses. This ASU is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 31, 2027. The Company is currently evaluating the effects of the pronouncement on its consolidated financial statements.

Basis of Presentation These accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company operates in two reportable segments.

Principles of Consolidation The consolidated financial statements include the accounts of Canton Strategic and its wholly-owned subsidiary, Gravitas. All significant intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Areas of the consolidated financial statements where estimates may have the most significant effect include fair value of cryptocurrency, research and development expense recognition, valuation of common shares and share-based compensation, allowances of deferred tax assets, valuation of debt related instruments, and cash flow assumptions regarding going concern considerations. Although management believes the estimates that have been used are reasonable, actual results could vary from the estimates that were used.

Segment Reporting As a result of the Company’s adopting a digital asset treasury strategy, the Company now has two reportable segments: digital assets and clinical stage bio-technology. The digital assets segment operates a CC-centric digital asset treasury strategy. The clinical stage bio-technology segment develops therapeutic candidates for rare, inflammatory and oncologic conditions. See Note 9 for additional information on the Company’s segments.

Concentration of Credit Risk The Company maintains cash balances with various financial institutions. Account balances at these institutions are insured by the Federal Deposit Insurance Corporation up to $250,000 per depositor. At various times during the year, bank account balances may have been in excess of federally insured limits. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

250000

Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents, if any, are stated at cost and consist primarily of money market accounts. Digital Assets The Company accounts for its digital assets, which are comprised of CC, as intangible assets in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 350-60, Intangibles—Goodwill and Other-Crypto Assets. The Company’s digital assets are initially recorded at cost and subsequently measured at fair value with the gain or loss associated with remeasurement of the digital assets recognized in net income (loss) during each reporting period. Upon disposal of a digital asset (e.g., by sale, exchange or transfer), the Company derecognizes the asset and recognizes a realized gain or loss in net income, calculated as the difference between the consideration received and the asset’s carrying amount. The fair value of the Company’s digital assets is determined based on quoted prices in its principal market at the time of measurement. The Company determines its principal market as the market that it has access to and has the greatest volume and level of orderly transactions in accordance with FASB ASC 820, Fair Value Measurement. The Company tracks the cost of its digital assets using the first-in-first-out (FIFO) method.

Research and Development Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials, and manufacture drug supplies and materials. These expenses also include costs associated with license fee arrangements and collaboration agreements, including milestone payments and ongoing license fees, which are also expensed as incurred. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by third parties, patient enrollment in clinical trials, administrative costs incurred by third parties, and other indicators of the services completed.

Stock-Based Compensation The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees, and directors as an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock-based award. The fair value of common stock issued pursuant to termination agreements as well as restricted stock or restricted stock units is generally measured as the grant-date price of the Company’s common stock. The fair value of each option grant to employees, non-employees, and directors is estimated as of the date of grant using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on the straight-line basis over the requisite service period of the awards, which is generally the vesting period. Prior to January 12, 2022, the Company was a private company and the Company’s common stock has only been publicly traded since that date. As a result, the Company has limited company-specific historical and implied volatility information. Therefore, it has estimated its expected stock volatility based on the historical data of a publicly traded set of peer companies. The expected term of stock options granted was between five and seven years. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant for time periods approximately equal to the expected term of the award.

Fair Value Measurements The Company applies FASB ASC Topic 820, Fair Value Measurement (“ASC 820”), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances. The carrying value of the Company’s cash, prepaid expenses, accounts payable, and accrued expenses approximate fair value because of the short-term maturity of these financial instruments. The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 Inputs: Observable inputs such as quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 Inputs: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for assets or liabilities recently traded in active markets, with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals, as well as quoted prices for identical or similar assets or liabilities in markets that are not active. </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 Inputs: Unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities, that reflect the reporting entity’s own assumptions.</td></tr> </table> The Company applies ASC 820 in the valuation of CC held by the Company for financial statement purposes. The fair value of CC uses Level 1 inputs to reflect the price that would be received for CC in a current sale, which assumes an orderly transaction between market participants on the measurement date in CC’s “principal market,” or in the absence of a principal market, the most advantageous market. Market participants are defined as buyers and sellers in the principal or most advantageous market that are independent, knowledgeable, and willing and able to transact. The Company determines its principal market (or in the absence of a principal market, the most advantageous market) on a periodic basis to determine which market is its principal market for the purpose of calculating fair value for the creation of quarterly and annual financial statements. Issuer-specific events, market trends, bid/ask quotes of brokers and information providers and other data may be reviewed in the course of making a good faith determination of the digital asset’s fair value.

Income Taxes The Company accounts for income taxes using the asset-and-liability method in accordance with FASB ASC Topic 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred income taxes are recognized for the tax effect of temporary differences between the financial statement carrying amount of assets and liabilities and the amounts used for income tax purposes and for certain changes in valuation allowances. Valuation allowances are recorded to reduce certain deferred tax assets when, in management’s estimation, it is more-likely-than-not that a tax benefit will not be realized. A full valuation allowance has been recognized for all periods since it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in future periods. The Company follows the guidance in FASB ASC Subtopic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely-than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more-likely-than-not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. At March 31, 2026 and December 31, 2025, the Company had no unrecognized uncertain income tax positions, and therefore no amounts have been recognized in the consolidated financial statements.

Patent Costs Costs associated with the submission of patent applications, including milestone fees and success fees, are expensed as incurred given the uncertainty of the future economic benefits of the patents. Patent and patent related legal and administrative costs are included in general and administrative expenses in the accompanying consolidated statements of operations.

Net Loss per Share The Company reports loss per share in accordance with FASB ASC Subtopic 260-10, Earnings Per Share, which provides for calculation of basic and diluted earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives effect to common stock equivalents; however, potential common shares are excluded if their effect is anti-dilutive. <p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zkAoNkaN8Sh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">Potentially dilutive securities not included in the computation of loss per share for the three months ended March 31, 2026 and 2025 are as follows: Schedule of Potentially Dilutive Equity Shares not Included in Computation of EPS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260101__20260331_z7BsEytA0qNj" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250101__20250331_zGPTO9xMkS0g" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended March 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z7d55QDU2rK2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Outstanding options to purchase shares of common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">656,163</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">242,788</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_ziMkqISUvQai" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants to purchase shares of common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13,239,833</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">928,676</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zwEqvZsFAXF8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">13,895,996</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,171,464</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zkAoNkaN8Sh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">Potentially dilutive securities not included in the computation of loss per share for the three months ended March 31, 2026 and 2025 are as follows: Schedule of Potentially Dilutive Equity Shares not Included in Computation of EPS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260101__20260331_z7BsEytA0qNj" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250101__20250331_zGPTO9xMkS0g" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended March 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z7d55QDU2rK2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Outstanding options to purchase shares of common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">656,163</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">242,788</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_ziMkqISUvQai" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants to purchase shares of common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13,239,833</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">928,676</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zwEqvZsFAXF8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">13,895,996</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,171,464</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

656163

242788

13239833

928676

13895996

1171464

Recent Accounting Pronouncements In December 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-08, Intangibles - Goodwill and Other - Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets. This standard requires certain crypto assets meeting defined criteria to be measured at fair value each reporting period with changes in fair value recognized in net income, presented separately from other intangible assets and accompanied by enhanced disclosures. This standard was effective for fiscal years beginning after December 15,2024, with early adoption permitted. The Company adopted this standard during the year ended December 31, 2025 in conjunction with its new treasury strategy. Since the Company held no digital assets until November 2025, the adoption of this standard had no impact to prior reported financial statements and no cumulative adjustment to retained earnings was required or recorded. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires expanded segment reporting and disclosure and is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted this guidance in the year ended December 31, 2025 as it previously did not have multiple reportable segments. This standard did not have a material impact on its financial statements other than enhanced disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which expands income tax footnote disclosure requirements, including rate reconciliation and income taxes paid disclosures. The standard is effective for fiscal years beginning after December 15, 2024. The ASU affects disclosure only and does not impact the recognition or measurement of income taxes under ASC 740. Accordingly, adoption of ASU 2023-09 had no impact on the Company’s income tax provision. In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses and in January 2025, the FASB issued ASU No. 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, which clarified the effective date of ASU 2024-03 for non-calendar year-end companies. ASU 2024-03 will require the Company to disclose the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization, as applicable, included in certain expense captions in the consolidated statements of operations, as well as qualitatively describe remaining amounts included in those captions. ASU 2024-03 will also require the Company to disclose both the amount and the Company’s definition of selling expenses. This ASU is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 31, 2027. The Company is currently evaluating the effects of the pronouncement on its consolidated financial statements.

Note 3 – Digital Assets The following table sets forth the units held, cost basis, and fair value of CC held, as shown on the consolidated balance sheet as of March 31, 2026 and December 31, 2025: Schedule of Digital Assets Held <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260331_zxpj14uP4eM5" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20251231_z1PVOflNiC77" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Canton Coin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_z6J0OSc3Tmo7" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Units held</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,677,150,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,339,567,946</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CryptoAssetCost_iI_zdYMiIeOwf4d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cost basis</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">578,593,029</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">523,770,731</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CryptoAssetFairValue_iI_zMkvzjaWyV62" style="vertical-align: bottom; background-color: White"> <td>Fair value</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">541,569,363</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">501,760,369</td><td style="text-align: left"> </td></tr> </table> Cost basis is equal to the cost of the digital asset, net of any transaction fees, if any, at the time of purchase or upon receipt. Fair value represents the quoted digital assets prices within the Company’s principal market at the time of measurement. The following table presents a reconciliation of digital assets held as of March 31, 2026: Schedule of Reconciliation of Digital Assets <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20260101__20260331_zwwZIBg5blf9" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CryptoAssetFairValue_iS_z2DnvwimOksg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Fair value, December 31, 2025 balance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">501,760,369</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CryptoAssetPurchase_zCk7SVckslhc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Additions from purchases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,822,298</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_zmYFOKRVk5P9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Unrealized losses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(15,013,304</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--CryptoAssetFairValue_iE_zPGqgBpRRHCl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Fair value, March 31, 2026 balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">541,569,363</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

The following table sets forth the units held, cost basis, and fair value of CC held, as shown on the consolidated balance sheet as of March 31, 2026 and December 31, 2025: Schedule of Digital Assets Held <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260331_zxpj14uP4eM5" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20251231_z1PVOflNiC77" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Canton Coin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_z6J0OSc3Tmo7" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Units held</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,677,150,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,339,567,946</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CryptoAssetCost_iI_zdYMiIeOwf4d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cost basis</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">578,593,029</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">523,770,731</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CryptoAssetFairValue_iI_zMkvzjaWyV62" style="vertical-align: bottom; background-color: White"> <td>Fair value</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">541,569,363</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">501,760,369</td><td style="text-align: left"> </td></tr> </table>

3677150850

3339567946

578593029

523770731

541569363

501760369

The following table presents a reconciliation of digital assets held as of March 31, 2026: Schedule of Reconciliation of Digital Assets <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20260101__20260331_zwwZIBg5blf9" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CryptoAssetFairValue_iS_z2DnvwimOksg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Fair value, December 31, 2025 balance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">501,760,369</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CryptoAssetPurchase_zCk7SVckslhc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Additions from purchases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,822,298</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_zmYFOKRVk5P9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Unrealized losses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(15,013,304</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--CryptoAssetFairValue_iE_zPGqgBpRRHCl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Fair value, March 31, 2026 balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">541,569,363</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

501760369

54822298

-15013304

541569363

Note 4 – Common Stock Pursuant to the Company’s Certificate of Incorporation, as amended (filed October 10, 2025), the Company has 1,000,000,000 (previously 250,000,000) shares of common stock authorized for issuance. On November 3, 2025, the Company entered into securities purchase agreements (the “Cash Securities Purchase Agreements”) with certain accredited investors (the “Cash Purchasers”) pursuant to which the Company agreed to sell and issue to the Cash Purchasers in a private placement offering (the “Cash Offering”) an aggregate of <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20251103__20251103__us-gaap--TypeOfArrangementAxis__custom--CashSecuritiesPurchaseAgreementsMember_zIkA8O4tYww" title="Aggregate sale amount of common stock">25,966,048 shares of common stock of the Company (the “Cash Shares”), par value $0.0001 per share (“Common Stock”) and/or pre-funded warrants (the “Cash Pre-Funded Warrants”) to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251103__us-gaap--TypeOfArrangementAxis__custom--CashSecuritiesPurchaseAgreementsMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zFixlz4xsDHi" title="Warrants to purchase shares">6,351,021 shares of Common Stock (the “Cash Pre-Funded Warrant Shares”) at an offering price of $3.075 per share (the “Per Share Cash Purchase Price”) for gross proceeds of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20251103__20251103__us-gaap--TypeOfArrangementAxis__custom--CashSecuritiesPurchaseAgreementsMember_zO3WuxBsbQY4" title="Proceeds from the common stock offering">99.4 million. Each of the Cash Pre-Funded Warrants is immediately exercisable for one share of Common Stock subject to certain beneficial ownership limitations set forth therein. Additionally, on November 3, 2025, the Company entered into securities purchase agreements (the “Cryptocurrency Securities Purchase Agreements”) with certain accredited investors (the “Cryptocurrency Purchasers”) pursuant to which the Company agreed to sell in a private placement (the “Cryptocurrency Offering”) pre-funded warrants (the “Cryptocurrency Pre-Funded Warrants”) to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251103__us-gaap--SubsidiarySaleOfStockAxis__custom--CryptocurrencyOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zMcGnpGn6i4l" title="Warrants to purchase shares">145,105,094 shares of Common Stock at an offering price of $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20251103__us-gaap--SubsidiarySaleOfStockAxis__custom--CryptocurrencyOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z4yWGUvAZ984" title="Price per share">3.075 for gross proceeds in Canton Coin of approximately $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20251103__20251103__us-gaap--SubsidiarySaleOfStockAxis__custom--CryptocurrencyOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zc9lldFkECXb" title="Gross proceeds from warrants">446.2 million. The Cryptocurrency Purchasers will tender Canton Coin to the Company as consideration for the Cryptocurrency Pre-Funded Warrants. The exercise of the Cryptocurrency Pre-Funded Warrants into Common Stock is subject to shareholder approval (“Shareholder Approval”) and such warrants will not be exercisable until such Shareholder Approval is received. Net proceeds to the Company from the combined Cash Offering and Cryptocurrency Offering were approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20251103__20251103__us-gaap--SubsidiarySaleOfStockAxis__custom--CashOfferingAndCryptocurrencyOfferingMember_zlnsvZkjk445" title="Net proceeds from offering">537.1 million after deducting $8.5 million in offering costs. Both the Cash Offering and Cryptocurrency Offering closed on November 6, 2025. In conjunction with the Cash Securities purchase Agreements and the Cryptocurrency Securities Purchase Agreements, the Company issued strategic advisor warrants to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251103__us-gaap--TypeOfArrangementAxis__custom--CashSecuritiesPurchaseAgreementsAndCrytocurrencySecuritiesPurchaseAgreementsMember__us-gaap--StatementEquityComponentsAxis__custom--StrategicAdvisorWarrantsMember_zSr9VYlGYTq3" title="Warrants to purchase common stock">10,318,215 shares of the Company’s common stock, exercisable at $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251103__us-gaap--TypeOfArrangementAxis__custom--CashSecuritiesPurchaseAgreementsAndCrytocurrencySecuritiesPurchaseAgreementsMember__us-gaap--StatementEquityComponentsAxis__custom--StrategicAdvisorWarrantsMember_zIvEZs0OLFJ5" title="Warrants exercise price per share">0.001 per share (the “Strategic Advisor Warrants”). In accordance with Nasdaq Listing Rule 5635(a), the issuance of shares pursuant to the Strategic Advisor Warrants were approved by shareholders on January 30, 2026. On November 6, 2025, the Company entered into an at-the-market agreement (the “2025 ATM Agreement”) with ClearStreet LLC and President Street Global LLC (the “ATM Sales Agents”) under which the Company may sell, from time to time through the ATM Sales Agents, shares of common stock in one or more offerings up to a total dollar amount of $<span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn6n6_c20251106__20251106__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFiveATMAgreementMember__srt--RangeAxis__srt--MaximumMember_zf4bC5v7PM44" title="Value of shares available for sale">65 million. On December 3, 2025 President Street Global LLC provided notice to the Company terminating participation in the 2025 ATM Agreement, leaving Clear Street LLC as the sole ATM Sales Agent. Sales of shares of the Company’s common stock through the ATM Sales Agent, if any, will be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the “Securities Act”), including, without limitation, sales made directly on the Nasdaq Stock Market LLC or any other existing trading market for the common shares. The Company’s common stock was being offered and sold pursuant to the Company’s effective shelf registration statement on Form S-3 and an accompanying prospectus declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on March 24, 2023, and pursuant to a prospectus supplement dated November 7, 2025. As of December 31, 2025, the Company had sold <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFiveATMAgreementMember_zYipqCvCreO7" title="Number of shares sold">1,657,799 shares of common stock pursuant to the 2025 ATM Agreement for net proceeds of approximately $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFiveATMAgreementMember_zHVUnbTnc1u1" title="Net proceeds from sale of shares">5.1 million after deducting commissions of approximately $0.1 million. On January 21, 2026, the Company closed an underwritten direct offering for 1,800,000 shares of its common stock, par value $0.0001 per share at an offering price of $2.92 per share and pre-funded warrants to purchase up to <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260121__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_ziYYuaznl8Qg" title="Warrants to purchase common stock">17,000,000 shares of common stock at an offering price of $2.9199 per pre-funded warrant. The exercise price of each pre-funded warrant is $0.0001 per share (the “January 2026 Offering”). Net proceeds to the Company for the January 2026 Offering were approximately $52.7 million after deducting $2.2 million in offering costs. The January 2026 Offering was made pursuant to the Company’s shelf registration statement on Form S-3 (Registration Statement No. 333-292648), including the prospectus included therein, previously filed with the Securities and Exchange Commission (the “SEC”) and which became effective on January 16, 2026, and a prospectus supplement and the accompanying prospectus filed with the SEC pursuant to Rule 424(b) under the Securities Act. On February 18, 2026, the Company’s common stock began trading under the ticker symbol, “CNTN.” On March 3, 2026, the Company entered into an amended and restated sales agreement (the “March 2026 ATM Agreement”), with Clear Street and Virtu Americas LLC (“Virtu”, and together with Clear Street, the “Sales Agents”), relating to the sale of shares of the Company’s common stock. The sales agreement amends and restates the 2025 ATM Agreement. Pursuant to the March 2026 ATM Agreement, the aggregate gross sales price of common stock available for issuance under the Sales Agreement is $<span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20260303__20260303__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentySixATMAgreementMember_zetHKFYe2b84" title="Number of shares sold value">300,000,000 and such amount excludes the common stock previously sold under the 2025 ATM Agreement. The Company’s common stock is being offered and sold pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration Statement No. 333-292648), including the prospectus included therein, previously filed with the SEC which became effective on January 16, 2026. For the three months ended March 31, 2026 the Company has sold <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFiveATMAgreementMember_zOh0RnN8mPLe" title="Number of shares sold">7,921,179 shares of common stock pursuant to the 2025 ATM Agreement and March 2026 ATM Agreement for net proceeds of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFiveATMAgreementMember_zRy8FOtJQsuh" title="Proceeds from sale of stock">35 million after deducting commissions of approximately $0.5 million.

1000000000

250000000

25966048

0.0001

6351021

3.075

99400000

145105094

3.075

446200000

537100000

8500000

10318215

0.001

65000000

1657799

5100000

100000

1800000

0.0001

2.92

17000000

2.9199

0.0001

52700000

2200000

300000000

7921179

35000000

500000

Note 5 – Stock Based Compensation Incentive Plans and Options Under the Company’s 2017 Stock Incentive Plan (the “2017 Plan”) the Company could grant incentive stock options, non-statutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock, performance shares, and performance units to employees, directors, and consultants of the Company and its affiliates. Up to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenStockIncentivePlanMember_znL8JnSBN6H9" title="Shares authorized for issuance">261 shares of the Company’s common stock could be issued pursuant to the 2017 Plan. The Company granted options to acquire <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenStockIncentivePlanMember_zO5rLa9ah7Fe" title="Options granted in period">255 shares of common stock at $4,950 per share under the 2017 Plan. During the three months ended March 31, 2026, options to acquire <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenStockIncentivePlanMember_zkxT0NzA4JT2" title="Number of shares available for forfeited">120 shares of common stock were forfeited. At March 31, 2026 there were no options outstanding. At December 31, 2025, there were <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenStockIncentivePlanMember_zLTFXoXnO6r9" title="Number of options, outstanding">120 options outstanding to acquire shares of common stock. In July 2019, the Company authorized the 2019 Stock Incentive Plan (the “2019 Plan”). Under the 2019 Plan, the Company could grant incentive stock options, non-statutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock, performance shares, and performance units to employees, directors, and consultants of the Company and its affiliates. The Company granted options to acquire <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwoThousandNineteenStockIncentivePlanMember_zLT6JyPW9V62" title="Options granted in period">10,452 shares of common stock under the 2019 Plan, of which <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwoThousandNineteenStockIncentivePlanMember_zu2wnAM0oCOk" title="Stock option, exercised">4,940 were exercised. During the three months ended March 31, 2026, options to acquire <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwoThousandNineteenStockIncentivePlanMember_zXqf9VSGR9E4" title="Number of shares available for forfeited">759 shares of common stock were forfeited. There are stock options outstanding to acquire <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandNineteenStockIncentivePlanMember_zvJqj3dIOS23" title="Number of options, outstanding">134 shares of common stock with a weighted-average exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandNineteenStockIncentivePlanMember_zuqQvboia26a" title="Weighted average exercise prices">498.75 and weighted average contractual terms of <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwoThousandNineteenStockIncentivePlanMember_zscxRkzPNTqk">6.0 years at March 31, 2026. At December 31, 2025 there were 893 options outstanding to acquire shares of common stock. On August 17, 2023, the Company authorized the Tharimmune, Inc., Inc. 2023 Omnibus Incentive Plan (as amended, the “2023 Plan”). Under the 2023 Plan, the Company may grant incentive stock options, non-statutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock, performance shares, and performance units to employees, directors, and consultants of the Company and its affiliates. Under an amendment and restatement to the 2023 Plan approved by the Company’s stockholders on May 14, 2024, an “evergreen” provision was added to automatically increase the number of shares available under the 2023 Plan on January 1 annually, beginning January 1, 2025 and ending January 1, 2033, equal to the lesser of five percent of the shares of common stock outstanding (on an as-converted basis) on the final day of the immediately preceding calendar year or such lesser number of shares of the Company’s common stock as determined by the Board of Directors. Effective January 1, 2025, an additional <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20250101__20250101__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zBrOBeYs3Al9" title="Number of shares authorized for issuance">98,688 shares of the Company’s common stock were added to the 2023 Plan, effective June 10, 2025, the shareholders approved an amendment to the 2023 Plan, increasing the 2023 Plan by <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20250610__20250610__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zmpVQeSozeRd" title="Number of shares authorized for issuance">520,314 shares, effective October 9, 2025, the shareholders approved an additional amendment to the 2023 Plan, increasing the 2023 Plan by <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20251009__20251009__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_z0rivkV00AZ2" title="Number of shares authorized for issuance">1,207,398 shares, to a total of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20251009__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zuPoO8AEFk43" title="Number of shares authorized for issuance">2,000,000 shares available under the 2023 Plan. On January 30, 2026 shareholders approved an amendment to the 2023 Plan, increasing the shares authorized by <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20260129__20260129__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zP9u0Ol1S8K4" title="Number of shares authorized for issuance">7,000,000 to a total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20260130__20260130__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_z6jvMOvtWcyh" title="Number of shares authorized for issuance">9,000,000. <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_znQeC1L9B63j" title="Number of shares authorized for issuance">7,793,342 and <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zt1A2pZOO7uc" title="Number of shares authorized for issuance">802,671 shares of common stock remained available for issuance under the 2023 Plan as of March 31, 2026 and December 31, 2025, respectively. During the three months ended March 31, 2026 and 2025, the Company granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zHDeOeiQCuG4" title="Options granted in period">0 and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zuYRkB4Y0ddf" title="Options granted in period">133,833 options to acquire shares of common stock under the 2023 Plan, respectively. During the three months ended March 31, 2026 and 2025, there were no options forfeited or exercises under the 2023 Plan. As of March 31, 2026 there were stock options outstanding to acquire <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zUT8i0mSCThb" title="Number of options, outstanding">656,029 shares of common stock with a weighted-average exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20260331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_z4VyUUh3q1P4" title="Weighted average exercise prices">1.94 and weighted-average contractual terms of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zLEZAkMVT5V1" title="Weighted average contractual term">9.3 years. The following table summarizes stock-based activities under the 2017 Plan, 2019 Plan, and 2023 Stock Incentive Plans: Schedule of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td><td> </td> <td style="text-align: center">Weighted</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Shares</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td><td> </td> <td style="text-align: center">Average</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Underlying</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td><td> </td> <td style="text-align: center">Contractual</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Terms</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding at December 31, 2025</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260331_zmuJOlwtOJ98" style="text-align: right; width: 14%" title="Shares underlying option, outstanding, beginning balance">657,042</td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260331_zMloWwk3ZGP5" style="text-align: right; width: 14%" title="Weighted average exercise price, outstanding, beginning balance">4.32</td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: right; width: 16%"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zvXSIuoRvUI6" title="Weighted average contractual terms outstanding">9.5 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20260101__20260331_zBsMwwkEGohc" style="border-bottom: Black 1pt solid; text-align: right" title="Shares underlying option, Forfeited">(879</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20260101__20260331_z0gVHihT9t6g" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited">1,626.87</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt">N/A</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260331_z3SyE7RRYkhk" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares underlying option, outstanding, ending balance">656,163</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260331_z9TIY9cuSZLl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding, ending balance">2.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331_z3jVIuo8F1O6" title="Weighted average contractual terms, outstanding">9.3 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Shares underlying option, outstanding, beginning balance"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Weighted average exercise price, outstanding, beginning balance"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable options at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260101__20260331_zJ5b1RbhVQ2d" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares underlying option, exercisable">656,163</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20260101__20260331_zDfR1ijOKOE9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">2.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331_z4v5LEehVHp2" title="Weighted average contractual terms, exercisable">9.3 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Shares underlying option, outstanding, beginning balance"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Weighted average exercise price, outstanding, beginning balance"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20260101__20260331_zO8mgepvfeUh" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares underlying option, vested and expected to vest">656,163</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260331_znUcdcYsBsl7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, vested and expected to vest">2.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331_z74qLJv5rTog" title="Weighted average contractual terms, vested and expected to vest">9.3 years</td></tr> </table> The fair value of stock option awards is estimated at the date of grant using the Black-Scholes option-pricing model. The estimated fair value of each stock option is then expensed over the requisite service period, which is generally the vesting period (ranging between immediate vesting and four years). The determination of fair value using the Black-Scholes model is affected by the Company’s share price as well as assumptions regarding a number of complex and subjective variables, including expected price volatility, expected life, risk-free interest rate and forfeitures. Forfeitures are accounted for as they occur. <p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zi77dbAFrCGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Stock options granted during the three months ended March 31, 2026 and 2025 were valued using the Black-Scholes option-pricing model with the following weighted-average assumptions: Schedule of Options Weighted Average Assumptions <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">For the three months ended March 31,</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2026</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2025</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify">Expected volatility</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"> N/A</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3hikg5Ejfwk" title="Expected volatility">102.3</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Risk-free interest rate</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">N/A</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8ZZ4oNeXu9g" title="Risk-free interest rate">4.61</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected dividend yield</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">N/A</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSgvpGZRUi5g" title="Expected dividend yield">0</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected life of options in years</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">N/A</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzaaIXqYCIa2" title="Expected life of options in years">5.0</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Estimated fair value of options granted</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">N/A</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdNkKKjwjn65" title="Estimated fair value of options granted">1.5</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table> There were no options granted in the three months ended March 31, 2026. The weighted-average grant date fair value of stock options granted during three months ended March 31, 2025 was approximately $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260331_z27wI4j9bHQ3" title="Weighted average grant date fair value of stock options granted">1.50. There were no options that vested in the three months ended March 31, 2026. All options granted were fully vested as of December 31, 2025. The weighted-average fair value of stock options vested during the three months ended March 31, 2025 was approximately $<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20250101__20250331_zUxo5tslJ3P4" title="Weighted average fair value of stock options vested">2.57. <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z9eaKjepgqWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">Total stock-based compensation expense included in the accompanying consolidated statements of operations was as follows: Schedule of Stock-Based Compensation Expense <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20260101__20260331_zwk66fo4ag4" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250101__20250331_zKApT6BW4Su8" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended March 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hcustom--StatementsOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_z9KeT9RXAUqi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">93,865</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_hcustom--StatementsOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zJcTEGsJspUk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">32,259,757</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">125,341</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_zIcYKWmEU92i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">32,259,757</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">219,179</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of March 31, 2026, there was no unrecognized compensation expense related to non-vested options. Warrants The Company has issued warrants to purchase shares of common stock in connection with various offerings, including those described in Note 4. The exercise of the Cryptocurrency Pre-Funded Warrants into common stock was subject to shareholder approval, and was approved on January 30, 2026 at a special meeting. The Strategic Advisor Warrants are compensatory and the issuance of shares pursuant to their exercise was approved by shareholders on January 30, 2026 so the Company recorded $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--StrategicAdvisorWarrantsMember_zAEjIDSnvnej" title="Stock based compensation expense">31,728,511 of stock based compensation expense for the three months ended March 31, 2026. The Strategic Advisory Warrants were valued at $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementClassOfStockAxis__custom--StrategicAdvisorWarrantsMember_zKKaWthx1btk" title="Warrants per share">3.075, the per share offering price of the Cash Offering and Cryptocurrency Offering which closed on November 6, 2025. Terms of the warrants outstanding at March 31, 2026 are as follows: Schedule of Warrants <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: center">Initial</td><td style="text-align: center; vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: center">Expiration</td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center">Exercise</td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center">Warrants</td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center">Warrants</td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center">Warrants</td><td style="text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Issuance Date</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Exercise Date</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Date</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Price</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Issued</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Exercised</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Outstanding</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 13%; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zf9Qj6O9TdXk" title="Warrants, Issuance Date">January 14, 2022</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; width: 13%; text-align: center; padding-bottom: 2.5pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zYCQMFifx4S4" title="Warrants, Initial Exercise Date">July 10, 2022</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; width: 13%; text-align: center; padding-bottom: 2.5pt">January 11, 2027</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zOXd9NVrI67g" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Warrants, Exercise Price">1,875.00</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_984_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zQjcm5YSxhid" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Warrants, Issued">500</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zKY34PIyb5Y" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Warrant, Exercised">-</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zZI2MoULM914" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Warrants, Outstanding">500</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zpIzIKlOVctg" title="Warrants, Issuance Date">May 2, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zV5pHTF1C3a7" title="Warrants, Initial Exercise Date">November 2, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">May 2, 2028</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_z52fRUnxQVm5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">234.375</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zLpc0um0cmph" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">424</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_z6kVCEZvUNX1" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant, Exercised">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zwB28PVhzYu" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">424</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zGflKhFtXsB8" title="Warrants, Issuance Date">November 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zMrxekBDRZNd" title="Warrants, Initial Exercise Date">May 27, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">May 2, 2028</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_ztjFyp4dBQ28" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">18.75</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zdlUnUD8hTa5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">20,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zmTLqAQVItTj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant, Exercised">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zWOZmPtffhy1" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">20,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zJsuaDgAbcni" title="Warrants, Issuance Date">June 21, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zk7ZKVk3RXQ4" title="Warrants, Initial Exercise Date">June 21, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zsFE9eDynxIc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zfTlonZtshyd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">452,253</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zQc47DtqTqN3" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">452,253</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_z8A4hSD5nrx" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zXpnBcWv99Ij" title="Warrants, Issuance Date">June 21, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zBEuKY8ImfIl" title="Warrants, Initial Exercise Date">June 21, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">December 21, 2029</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zUSELD8SvOmc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">3.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zLnmSfpRrbk2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">329,771</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zsMD1WaPczvb" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">229,430</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zsYiLHPSvao7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">100,341</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zoxijq3vr362" title="Warrants, Issuance Date">June 21, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zDj6cFuql9m7" title="Warrants, Initial Exercise Date">June 21, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">December 21, 2029</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zcfGALF3ijX6" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">3.06</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zNE6qdoNx2Zk" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">39,573</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zwn9xnPCcoI7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_ztIhemwCBbg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">39,573</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_zUERUvJlVFKi" title="Warrants, Issuance Date">December 9, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_z1PoT9wUMd48" title="Warrants, Initial Exercise Date">December 9, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_z8d2IBn4h71g" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_z9DGE3vU59W" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">491,157</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_zIRRkn96ovwg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">491,157</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_zmHibO2MIvea" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zMhe2imTYhJ1" title="Warrants, Issuance Date">December 9, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zlSxiEQ276nb" title="Warrants, Initial Exercise Date">June 9, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">December 9, 2030</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zx4sXxAmwmc9" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">2.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zptA2L8ZR6e5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">480,721</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zEACYOZDBHP7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">317,673</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zrastsCUenGb" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">163,048</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_zEm9grZXw2qb" title="Warrants, Issuance Date">December 9, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_zyzjCyVCwyde" title="Warrants, Initial Exercise Date">June 9, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">December 9, 2030</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_zZ0Kl78SrCSe" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">2.031</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_zPcEvyyy0jH5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">57,687</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_zB0EbnxTnO5h" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_z2lSCv8wAPnf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">57,687</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zgiZjH42O7Qg" title="Warrants, Issuance Date">June 20, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zJh230yZdGsf" title="Warrants, Initial Exercise Date">June 20, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zTJ8Aa5vWLL5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zaavwvTC7eh2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">137,838</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zBYMH5Y5Ad65" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">137,838</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zBjHbTXWvW2b" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90D_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_z7KizX6ROQ8l" title="Warrants, Issuance Date">June 20, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_fKg_____z9Zl2tGyFmr5" title="Warrants, Initial Exercise Date">December 20, 2025*</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_fKg_____zLZI3zsm2WQd" title="Warrants, Expiration Date">June 20, 2031*</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_zubjVJBhmH19" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">1.29</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_zqvZ8VsaM57" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">1,689,189</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_zTv6jyObelw9" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">858,111</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_zN3QAp1sajoh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">831,078</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_zc1RidI7n9Q3" title="Warrants, Issuance Date">June 20, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_fKg_____zRGC66dL1gV2" title="Warrants, Initial Exercise Date">December 20, 2025*</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_fKg_____zjY3pouJSO78" title="Warrants, Expiration Date">June 20, 2031*</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_zg1pHMsvievb" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">3.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_zK2LSDQQ3Efg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">844,570</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_zrBuTIzxMW78" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">114,862</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_ze7GtBlmTqJ5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">729,708</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_z4IETqedFlea" title="Warrants, Issuance Date">June 20, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_zd7cujuSc6ui" title="Warrants, Initial Exercise Date">December 20, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">June 20, 2031</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_z5TMcx6mEDKj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">1.29</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_znJGgoOg5dt9" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">118,243</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_zLm67n86h1dd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">6,739</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_ztOtFcGE4zt5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">111,504</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zl1lxczpY247" title="Warrants, Issuance Date">June 20, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zgzfueEA2V6k" title="Warrants, Initial Exercise Date">December 20, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">June 20, 2031</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_z2dIg0EGFRl4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">3.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zOfmVV2v68tj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">59,119</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zlsxzBrM5N5d" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zJm67AvRhAU2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">59,119</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zpay7DATyYzk" title="Warrants, Issuance Date">July 25, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zcpzUExLQSUc" title="Warrants, Initial Exercise Date">July 25, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zWbwr38spkib" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_z0vtPGsw31L3" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">559,910</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zNJ9zPLFW2ad" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">559,910</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zCz4J7sNkJHd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_zdYB17w4atid" title="Warrants, Issuance Date">July 25, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_fKg_____zFU7ad8L0oz5" title="Warrants, Initial Exercise Date">January 25, 2026*</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_fKg_____zcwauk5wgKLg" title="Warrants, Expiration Date">July 25, 2031*</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_zyLvEdPk5iSc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">1.66</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_zbuPL1VT5qhc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">974,241</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_zAuNw6F4U7W5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">260,354</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_zNS40gzSiL66" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">713,887</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_znDov26gBs32" title="Warrants, Issuance Date">July 25, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_zUfA6ugLIKce" title="Warrants, Initial Exercise Date">July 25, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_zXhu6kxFS0q7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_zCmU45LFAGfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">103,490</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_zWRA2drOiPM5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">103,490</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_z70sj325UPl8" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90D_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_ztMjdJYlSkvd" title="Warrants, Issuance Date">July 25, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_fKg_____zjh4NavKKyLj" title="Warrants, Initial Exercise Date">January 25, 2026*</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_fKg_____z4hJdrEjhNca" title="Warrants, Expiration Date">July 25, 2031*</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_zrTXYLWDIed4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">1.52</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_zv5p9FfasRT6" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">744,680</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_zG6QB9xcvKZf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">699,088</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_zrhNWUGydl3i" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">45,592</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_zhL4lN7xdbYc" title="Warrants, Issuance Date">July 25, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_z7TR7NkWHI74" title="Warrants, Initial Exercise Date">January 25, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">July 25, 2031</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_zXduHQyWFym4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">1.66</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_z9E8owkV9va8" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">52,128</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_z0THY3YGqQN3" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">2,971</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_zOEmSck3azkl" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">49,157</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_zhaUGSGE13Z6" title="Warrants, Issuance Date">August 26, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_zPRHShvnVZGf" title="Warrants, Initial Exercise Date">August 26, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_z1ur2xkWG7dg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_zpJYnNTU4T9i" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">983,111</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_z7OwqlFJe4g2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">983,111</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_zI9cFMaTbdVg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_zRZDTKFOD4Sf" title="Warrants, Issuance Date">November 6, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_z079x17Y2OJj" title="Warrants, Initial Exercise Date">November 6, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_z7Cnk8XbkvZ5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_zSJkhqXk4bJg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">6,351,021</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_zRkGbVrH4k3f" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_zN9PNZ71NA37" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">6,351,021</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_zh5FYp709wz9" title="Warrants, Issuance Date">November 6, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_z3xTAUqfCt47" title="Warrants, Initial Exercise Date">November 6, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_zR2bo5ukXZn5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_z39MR4XIVfq1" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">145,105,094</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_zZzxhbRZjj0f" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">9,590,012</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_zeJFzd5HL022" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">135,515,082</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_zwdNLi0jZaSe" title="Warrants, Issuance Date">November 6, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_zhneop9dbUE4" title="Warrants, Initial Exercise Date">January 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_zs9pzWLVxHkc" title="Warrants, Expiration Date">January 30, 2031</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_z0OD8uThKTOe" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_zOE0f5WQdbTc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">10,318,215</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_zGW2c5cN2mgg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_z232XVPKZYzl" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">10,318,215</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_zKkaatEMz9ac" title="Warrants, Issuance Date">January 21, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_zmQZtBPI0oV3" title="Warrants, Initial Exercise Date">January 21, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_zUDLirUVMDX2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">.0001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_zER9Y15X96hl" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">17,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_z3nWUeYpsGyl" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_zxtNiRogYMB" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">17,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">*</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The exercise and expiration dates for the referenced common warrants were amended in October 2025 to reflect an exercise date of October 1, 2025.</td></tr> </table> Restricted Stock Units During the three months ended March 31, 2025, as stock-based consideration for consulting services, the Company granted restricted stock units (“RSUs”) under the 2023 Plan representing the right to receive 35,000 shares of the Company’s common stock. During the three months ended March 31, 2026 as stock-based consideration for consulting services, the Company granted RSUs under the 2023 Plan representing the right to receive 15,000 shares of the Company’s common stock. <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLdp3Su0hnQl" title="Restricted stock units, description">The RSUs will 100% vest on June 30, 2026, provided that the grantee remains a consultant of the Company. The grant date fair value of an RSU represents the closing price of the Company’s common stock on the date of grant. For those not vesting immediately, the estimated fair value of each RSU is then expensed over the requisite service period, which is generally the vesting period. The total stock compensation expense related to RSUs for the three months ended March 31, 2026 and 2025 was $31,248 and $8,274, respectively. The total estimated fair value of unvested RSUs at March 31, 2026 was $<span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardRestrictedStockUnitsInPeriodFairValue_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEKG6vvIBpXh" title="Total fair value of RSUs">146,075, of which $<span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7ft7bbBHCQe" title="Unrecognized sharebased compensation remaining to be expensed">69,857 remains to be vested quarterly through June 30, 2026. As of March 31, 2026, there are <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQEpPo88Ueil" title="Nonvested number of shares">50,000 outstanding unvested RSUs, which will fully vest on June 30, 2026. During the three months ended March 31, 2026 the Company issued 162,601 shares of common stock to Clear Street LLC in connection with their services as an advisor in the Cash Offering and Cryptocurrency Offering which closed on November 6, 2025 (the “Advisor RSUs”). The Advisor RSUs share issuance was approved by shareholders during a special meeting on January 30, 2026. The Advisor RSUs were valued at $3.075 per share, the per share offering price of the Cash Offering and Cryptocurrency Offering which closed on November 6, 2025. The company recorded $499,998 of stock compensation expense related to the Advisor RSUs for the three months ended March 31, 2026.

261

255

4950

120

10452

4940

759

134

498.75

P6Y

98688

520314

1207398

2000000

7000000

9000000

7793342

802671

133833

656029

1.94

P9Y3M18D

The following table summarizes stock-based activities under the 2017 Plan, 2019 Plan, and 2023 Stock Incentive Plans: Schedule of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td><td> </td> <td style="text-align: center">Weighted</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Shares</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td><td> </td> <td style="text-align: center">Average</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Underlying</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td><td> </td> <td style="text-align: center">Contractual</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Terms</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding at December 31, 2025</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260331_zmuJOlwtOJ98" style="text-align: right; width: 14%" title="Shares underlying option, outstanding, beginning balance">657,042</td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260331_zMloWwk3ZGP5" style="text-align: right; width: 14%" title="Weighted average exercise price, outstanding, beginning balance">4.32</td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: right; width: 16%"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zvXSIuoRvUI6" title="Weighted average contractual terms outstanding">9.5 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20260101__20260331_zBsMwwkEGohc" style="border-bottom: Black 1pt solid; text-align: right" title="Shares underlying option, Forfeited">(879</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20260101__20260331_z0gVHihT9t6g" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited">1,626.87</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt">N/A</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260331_z3SyE7RRYkhk" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares underlying option, outstanding, ending balance">656,163</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260331_z9TIY9cuSZLl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding, ending balance">2.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331_z3jVIuo8F1O6" title="Weighted average contractual terms, outstanding">9.3 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Shares underlying option, outstanding, beginning balance"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Weighted average exercise price, outstanding, beginning balance"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable options at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260101__20260331_zJ5b1RbhVQ2d" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares underlying option, exercisable">656,163</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20260101__20260331_zDfR1ijOKOE9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">2.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331_z4v5LEehVHp2" title="Weighted average contractual terms, exercisable">9.3 years</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Shares underlying option, outstanding, beginning balance"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Weighted average exercise price, outstanding, beginning balance"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20260101__20260331_zO8mgepvfeUh" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares underlying option, vested and expected to vest">656,163</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260331_znUcdcYsBsl7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, vested and expected to vest">2.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331_z74qLJv5rTog" title="Weighted average contractual terms, vested and expected to vest">9.3 years</td></tr> </table>

657042

4.32

P9Y6M

879

1626.87

656163

2.04

P9Y3M18D

656163

2.04

P9Y3M18D

656163

2.04

P9Y3M18D

<p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zi77dbAFrCGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Stock options granted during the three months ended March 31, 2026 and 2025 were valued using the Black-Scholes option-pricing model with the following weighted-average assumptions: Schedule of Options Weighted Average Assumptions <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">For the three months ended March 31,</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2026</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2025</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify">Expected volatility</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"> N/A</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3hikg5Ejfwk" title="Expected volatility">102.3</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Risk-free interest rate</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">N/A</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8ZZ4oNeXu9g" title="Risk-free interest rate">4.61</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected dividend yield</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">N/A</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSgvpGZRUi5g" title="Expected dividend yield">0</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected life of options in years</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">N/A</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzaaIXqYCIa2" title="Expected life of options in years">5.0</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Estimated fair value of options granted</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">N/A</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20250331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdNkKKjwjn65" title="Estimated fair value of options granted">1.5</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>

1.023

0.0461

P5Y

1.5

1.50

2.57

<p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z9eaKjepgqWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">Total stock-based compensation expense included in the accompanying consolidated statements of operations was as follows: Schedule of Stock-Based Compensation Expense <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20260101__20260331_zwk66fo4ag4" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250101__20250331_zKApT6BW4Su8" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended March 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hcustom--StatementsOfIncomeLocationBalanceAxis__custom--ResearchAndDevelopmentExpensesMember_z9KeT9RXAUqi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">93,865</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AllocatedShareBasedCompensationExpense_hcustom--StatementsOfIncomeLocationBalanceAxis__custom--GeneralAndAdministrativeExpensesMember_zJcTEGsJspUk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">32,259,757</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">125,341</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_zIcYKWmEU92i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">32,259,757</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">219,179</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

93865

32259757

125341

32259757

219179

31728511

3.075

Terms of the warrants outstanding at March 31, 2026 are as follows: Schedule of Warrants <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; text-align: center"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: center">Initial</td><td style="text-align: center; vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: center">Expiration</td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center">Exercise</td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center">Warrants</td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center">Warrants</td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom; text-align: center">Warrants</td><td style="text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Issuance Date</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Exercise Date</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Date</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Price</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Issued</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Exercised</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Outstanding</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 13%; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zf9Qj6O9TdXk" title="Warrants, Issuance Date">January 14, 2022</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; width: 13%; text-align: center; padding-bottom: 2.5pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zYCQMFifx4S4" title="Warrants, Initial Exercise Date">July 10, 2022</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; width: 13%; text-align: center; padding-bottom: 2.5pt">January 11, 2027</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zOXd9NVrI67g" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Warrants, Exercise Price">1,875.00</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_984_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zQjcm5YSxhid" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Warrants, Issued">500</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zKY34PIyb5Y" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Warrant, Exercised">-</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zZI2MoULM914" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Warrants, Outstanding">500</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zpIzIKlOVctg" title="Warrants, Issuance Date">May 2, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zV5pHTF1C3a7" title="Warrants, Initial Exercise Date">November 2, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">May 2, 2028</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_z52fRUnxQVm5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">234.375</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zLpc0um0cmph" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">424</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_z6kVCEZvUNX1" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant, Exercised">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zwB28PVhzYu" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">424</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zGflKhFtXsB8" title="Warrants, Issuance Date">November 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zMrxekBDRZNd" title="Warrants, Initial Exercise Date">May 27, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">May 2, 2028</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_ztjFyp4dBQ28" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">18.75</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zdlUnUD8hTa5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">20,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zmTLqAQVItTj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant, Exercised">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zWOZmPtffhy1" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">20,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zJsuaDgAbcni" title="Warrants, Issuance Date">June 21, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zk7ZKVk3RXQ4" title="Warrants, Initial Exercise Date">June 21, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zsFE9eDynxIc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zfTlonZtshyd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">452,253</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zQc47DtqTqN3" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">452,253</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_z8A4hSD5nrx" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zXpnBcWv99Ij" title="Warrants, Issuance Date">June 21, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zBEuKY8ImfIl" title="Warrants, Initial Exercise Date">June 21, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">December 21, 2029</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zUSELD8SvOmc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">3.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zLnmSfpRrbk2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">329,771</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zsMD1WaPczvb" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">229,430</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zsYiLHPSvao7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">100,341</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zoxijq3vr362" title="Warrants, Issuance Date">June 21, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zDj6cFuql9m7" title="Warrants, Initial Exercise Date">June 21, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">December 21, 2029</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zcfGALF3ijX6" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">3.06</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zNE6qdoNx2Zk" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">39,573</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zwn9xnPCcoI7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_ztIhemwCBbg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">39,573</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_zUERUvJlVFKi" title="Warrants, Issuance Date">December 9, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_z1PoT9wUMd48" title="Warrants, Initial Exercise Date">December 9, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_z8d2IBn4h71g" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_z9DGE3vU59W" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">491,157</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_zIRRkn96ovwg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">491,157</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_zmHibO2MIvea" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zMhe2imTYhJ1" title="Warrants, Issuance Date">December 9, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zlSxiEQ276nb" title="Warrants, Initial Exercise Date">June 9, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">December 9, 2030</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zx4sXxAmwmc9" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">2.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zptA2L8ZR6e5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">480,721</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zEACYOZDBHP7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">317,673</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zrastsCUenGb" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">163,048</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_zEm9grZXw2qb" title="Warrants, Issuance Date">December 9, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_zyzjCyVCwyde" title="Warrants, Initial Exercise Date">June 9, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">December 9, 2030</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_zZ0Kl78SrCSe" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">2.031</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_zPcEvyyy0jH5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">57,687</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_zB0EbnxTnO5h" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_z2lSCv8wAPnf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">57,687</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zgiZjH42O7Qg" title="Warrants, Issuance Date">June 20, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zJh230yZdGsf" title="Warrants, Initial Exercise Date">June 20, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zTJ8Aa5vWLL5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zaavwvTC7eh2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">137,838</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zBYMH5Y5Ad65" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">137,838</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zBjHbTXWvW2b" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90D_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_z7KizX6ROQ8l" title="Warrants, Issuance Date">June 20, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_fKg_____z9Zl2tGyFmr5" title="Warrants, Initial Exercise Date">December 20, 2025*</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_fKg_____zLZI3zsm2WQd" title="Warrants, Expiration Date">June 20, 2031*</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_zubjVJBhmH19" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">1.29</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_zqvZ8VsaM57" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">1,689,189</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_zTv6jyObelw9" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">858,111</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_zN3QAp1sajoh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">831,078</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_zc1RidI7n9Q3" title="Warrants, Issuance Date">June 20, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_fKg_____zRGC66dL1gV2" title="Warrants, Initial Exercise Date">December 20, 2025*</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_fKg_____zjY3pouJSO78" title="Warrants, Expiration Date">June 20, 2031*</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_zg1pHMsvievb" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">3.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_zK2LSDQQ3Efg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">844,570</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_zrBuTIzxMW78" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">114,862</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_ze7GtBlmTqJ5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">729,708</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_z4IETqedFlea" title="Warrants, Issuance Date">June 20, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_zd7cujuSc6ui" title="Warrants, Initial Exercise Date">December 20, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">June 20, 2031</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_z5TMcx6mEDKj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">1.29</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_znJGgoOg5dt9" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">118,243</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_zLm67n86h1dd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">6,739</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_ztOtFcGE4zt5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">111,504</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zl1lxczpY247" title="Warrants, Issuance Date">June 20, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zgzfueEA2V6k" title="Warrants, Initial Exercise Date">December 20, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">June 20, 2031</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_z2dIg0EGFRl4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">3.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zOfmVV2v68tj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">59,119</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zlsxzBrM5N5d" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zJm67AvRhAU2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">59,119</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zpay7DATyYzk" title="Warrants, Issuance Date">July 25, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zcpzUExLQSUc" title="Warrants, Initial Exercise Date">July 25, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zWbwr38spkib" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_z0vtPGsw31L3" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">559,910</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zNJ9zPLFW2ad" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">559,910</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zCz4J7sNkJHd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_zdYB17w4atid" title="Warrants, Issuance Date">July 25, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_fKg_____zFU7ad8L0oz5" title="Warrants, Initial Exercise Date">January 25, 2026*</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_fKg_____zcwauk5wgKLg" title="Warrants, Expiration Date">July 25, 2031*</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_zyLvEdPk5iSc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">1.66</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_zbuPL1VT5qhc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">974,241</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_zAuNw6F4U7W5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">260,354</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_zNS40gzSiL66" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">713,887</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_znDov26gBs32" title="Warrants, Issuance Date">July 25, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_zUfA6ugLIKce" title="Warrants, Initial Exercise Date">July 25, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_zXhu6kxFS0q7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_zCmU45LFAGfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">103,490</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_zWRA2drOiPM5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">103,490</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_z70sj325UPl8" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90D_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_ztMjdJYlSkvd" title="Warrants, Issuance Date">July 25, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_fKg_____zjh4NavKKyLj" title="Warrants, Initial Exercise Date">January 25, 2026*</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_fKg_____z4hJdrEjhNca" title="Warrants, Expiration Date">July 25, 2031*</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_zrTXYLWDIed4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">1.52</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_zv5p9FfasRT6" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">744,680</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_zG6QB9xcvKZf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">699,088</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_zrhNWUGydl3i" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">45,592</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_zhL4lN7xdbYc" title="Warrants, Issuance Date">July 25, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_z7TR7NkWHI74" title="Warrants, Initial Exercise Date">January 25, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">July 25, 2031</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_zXduHQyWFym4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">1.66</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_z9E8owkV9va8" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">52,128</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_z0THY3YGqQN3" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">2,971</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_zOEmSck3azkl" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">49,157</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_zhaUGSGE13Z6" title="Warrants, Issuance Date">August 26, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_zPRHShvnVZGf" title="Warrants, Initial Exercise Date">August 26, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_z1ur2xkWG7dg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_zpJYnNTU4T9i" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">983,111</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_z7OwqlFJe4g2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">983,111</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_zI9cFMaTbdVg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_zRZDTKFOD4Sf" title="Warrants, Issuance Date">November 6, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_z079x17Y2OJj" title="Warrants, Initial Exercise Date">November 6, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_z7Cnk8XbkvZ5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_zSJkhqXk4bJg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">6,351,021</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_zRkGbVrH4k3f" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_zN9PNZ71NA37" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">6,351,021</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_zh5FYp709wz9" title="Warrants, Issuance Date">November 6, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_z3xTAUqfCt47" title="Warrants, Initial Exercise Date">November 6, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_zR2bo5ukXZn5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_z39MR4XIVfq1" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">145,105,094</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_zZzxhbRZjj0f" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">9,590,012</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_zeJFzd5HL022" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">135,515,082</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_zwdNLi0jZaSe" title="Warrants, Issuance Date">November 6, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_zhneop9dbUE4" title="Warrants, Initial Exercise Date">January 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_zs9pzWLVxHkc" title="Warrants, Expiration Date">January 30, 2031</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_z0OD8uThKTOe" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_zOE0f5WQdbTc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">10,318,215</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_zGW2c5cN2mgg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_z232XVPKZYzl" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">10,318,215</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="vertical-align: top; text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_zKkaatEMz9ac" title="Warrants, Issuance Date">January 21, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_zmQZtBPI0oV3" title="Warrants, Initial Exercise Date">January 21, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_zUDLirUVMDX2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">.0001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightIssued_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_zER9Y15X96hl" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">17,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_ecustom--ClassOfWarrantExercised_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_z3nWUeYpsGyl" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260331__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_zxtNiRogYMB" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">17,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">*</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The exercise and expiration dates for the referenced common warrants were amended in October 2025 to reflect an exercise date of October 1, 2025.</td></tr> </table>

2022-01-14

2022-07-10

2027-01-11

1875.00

500

2023-05-02

2023-11-02

2028-05-02

234.375

424

2023-11-30

2024-05-27

2028-05-02

18.75

20000

2024-06-21

0.001

452253 452253 2024-06-21

2024-06-21

2029-12-21

3.09

329771 229430

100341

2024-06-21

2029-12-21

3.06

39573

2024-12-09

0.001

491157 491157 2024-12-09

2025-06-09

2030-12-09

2.03

480721 317673

163048

2024-12-09

2025-06-09

2030-12-09

2.031

57687

2025-06-20

0.001

137838 137838 2025-06-20

2025-12-20

2031-06-20

1.29

1689189 858111

831078

2025-06-20

2025-12-20

2031-06-20

3.00

844570 114862

729708

2025-06-20

2025-12-20

2031-06-20

1.29

118243 6739

111504

2025-06-20

2025-12-20

2031-06-20

3.00

59119

2025-07-25

0.001

559910 559910 2025-07-25

2026-01-25

2031-07-25

1.66

974241 260354

713887

2025-07-25

0.001

103490 103490 2025-07-25

2026-01-25

2031-07-25

1.52

744680 699088

45592

2025-07-25

2026-01-25

2031-07-25

1.66

52128 2971

49157

2025-08-26

2026-08-26

0.001

983111 983111 2025-11-06

2025-11-06

0.001

6351021

2025-11-06

145105094 9590012

135515082

2025-11-06

2026-01-30

2031-01-30

0.001

10318215

2026-01-21

0.0001

17000000

35000

15000

The RSUs will 100% vest on June 30, 2026, provided that the grantee remains a consultant of the Company.

31248

8274

146075

69857

50000

162601

3.075

499998

Note 6 – Income Taxes The following table presents the income tax provision (benefit) and effective tax rate: Schedule of Effective Income Tax Rate and Income Tax Provision (benefit) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Income tax provision (benefit)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--IncomeTaxExpenseBenefit_c20260101__20260331_zAUe1ZUGYCC1" style="width: 16%; text-align: right" title="Effective income tax expense">(4,220,240</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--IncomeTaxExpenseBenefit_c20250101__20250331_zAwskEHkLilh" style="width: 16%; text-align: right" title="Income tax provision (benefit)">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effective tax rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_c20260101__20260331_zuvHkTuLjRRg" style="text-align: right" title="Effective income tax expense, percentage">8.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_c20250101__20250331_zspZZdT6lcgh" style="text-align: right" title="Effective income tax">-</td><td style="text-align: left"> </td></tr> </table> The effective tax rate reflects a full valuation allowance against net deferred tax assets, including tax loss carryforwards. The Company has recognized a deferred tax provision (benefit) in connection with unrealized gains or losses on Digital Assets.

The following table presents the income tax provision (benefit) and effective tax rate: Schedule of Effective Income Tax Rate and Income Tax Provision (benefit) <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Income tax provision (benefit)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--IncomeTaxExpenseBenefit_c20260101__20260331_zAUe1ZUGYCC1" style="width: 16%; text-align: right" title="Effective income tax expense">(4,220,240</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--IncomeTaxExpenseBenefit_c20250101__20250331_zAwskEHkLilh" style="width: 16%; text-align: right" title="Income tax provision (benefit)">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effective tax rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_c20260101__20260331_zuvHkTuLjRRg" style="text-align: right" title="Effective income tax expense, percentage">8.2</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_c20250101__20250331_zspZZdT6lcgh" style="text-align: right" title="Effective income tax">-</td><td style="text-align: left"> </td></tr> </table>

-4220240

0.082

Note 7 – Commitments and Contingencies Research Collaboration and Product License Agreement with Minotaur Therapeutics, Inc. (“Minotaur”) and Commercial License Agreement with Taurus Biosciences, LLC (“Taurus”) The Company has entered into a research collaboration and product license agreement with Minotaur (as amended, the “Minotaur Agreement”) and a commercial license agreement with Taurus (the “Taurus Agreement”) for use of certain technology, including OmniAb antibodies, to advance Picobodies against novel, unreachable, and undruggable epitopes in high-value validated targets starting with PD-1. The Minotaur Agreement and Taurus Agreement are for the development of proprietary targeted biologics, including GV1940, against PD-1. It is anticipated that the Company will collaborate with Minotaur under the license from Taurus to discover, develop, and advance biotherapeutics against high-value validated IO targets starting with PD-1. The Minotaur Agreement included an up-front payment of $150,000, which was paid in January 2023. In addition, the Company shall fund the discovery and characterization study performed by Minotaur as set forth in the Minotaur Agreement. Pursuant to the Minotaur Agreement, the Company shall pay Minotaur a milestone payment of $1,000,000 for each first Product (as defined in the Minotaur Agreement) directed against a target and first regulatory approval in the U.S. In addition, the Company shall pay a low single digit royalty on net sales until the later of (i) ten years after the First Commercial Sale (as defined in the Minotaur Agreement) of such Product in such country and (ii) the expiration of the last-to-expire Valid Claim (as defined in the Minotaur Agreement) of a Collaboration Patent (as defined in the Minotaur Agreement) or MINT Patent (as defined in the Minotaur Agreement) covering the manufacture, use, or sale of such Product. The Taurus Agreement contains single digit payments on net product sales and certain development milestone payments tied to the advancement through clinical trials and final regulatory approval. During the three months ended March 31, 2026 and 2025, the Company incurred no fees to Minotaur. Research and Development Collaboration and License Agreement with Applied Biomedical Science Institute On July 5, 2023 (the “ABSI Effective Date”), the Company entered into a Research and Development Collaboration and License Agreement (the “ABSI Agreement”) with ABSI pursuant to which ABSI granted the Company an exclusive royalty-bearing, sublicensable license to the ABSI Patents (as defined in the ABSI Agreement) and a non-exclusive, royalty-bearing, sublicensable license to the ABSI Know-How (as defined in the ABSI Agreement) to Exploit (as defined in the ABSI Agreement) the ABSI Products (as defined in the ABSI Agreement) for the treatment, diagnosis, prediction, detection or prevention of disease in humans and animals worldwide (the “Territory”). Pursuant to the ABSI Agreement, the parties shall form a committee to manage the preclinical, investigational new drug enabling studies and such other activities as shall lead to the initiation of a Phase 1 clinical trial of the ABSI Product. The parties will collaborate on a Target-by-Target basis to identify and evaluate ABSI Products directed against such Target (as defined below) with a view to identifying or generating suitable Products (as defined in the ABSI Agreement) for the Company to Exploit. “Target” means ErB2 (Her2) and ErbB3. Upon completion of the Discovery Timeline (as defined in the ABSI Agreement) for a Target, subject to the terms and conditions of ABSI Agreement, the Company shall exclusively own any ABSI Products against such Target. In the event the committee determines that the discovery activities are unsuccessful with respect to a Target, the Company may propose an additional target, which, upon approval by ABSI, shall replace a failed Target. Pursuant to the ABSI Agreement: (i) the Company issued ABSI <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230727__20230727__us-gaap--TypeOfArrangementAxis__custom--AppliedBiomedicalScienceInstituteMember_zypw4K8s0oQ5" title="Common stock issued">25,107 shares of its common stock which is equal to $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230727__20230727__us-gaap--TypeOfArrangementAxis__custom--AppliedBiomedicalScienceInstituteMember_zDx6MxTgIOa" title="Value of common stock issued">250,000 based on the ten day trailing volume weighted-average price of the Company’s common stock prior to the date of issuance, (ii) in the event the Company closes a financing pursuant to which it receives more than $10 million in Net Proceeds (as defined in the ABSI Agreement), the Company shall pay ABSI a mid-six digit amount; (iii) upon the achievement of certain milestones as set forth in the ABSI Agreement, the Company shall pay ABSI up to an aggregate of $<span id="xdx_908_ecustom--MilestonePayment_c20230704__20230705__us-gaap--TypeOfArrangementAxis__custom--AppliedBiomedicalScienceInstituteMember__srt--RangeAxis__srt--MaximumMember_zPvMDzc4LMnc" title="ABSI shares issued, shares">8,250,000; (iv) after the second anniversary of the ABSI Effective Date, the Company shall pay ABSI a low five digit amount for the first year and a mid-five digit amount thereafter during the Royalty Term (as defined in the ABSI Agreement); and (v) during the Royalty Term for each Product, the Company shall pay ABSI a quarterly royalty on the Net Sales (as defined in the ABSI Agreement) with royalties at percentages which range from the low to mid-single digits, with high Net Sales being subject to lower royalty rates, subject to adjustment as set forth in the ABSI Agreement. In addition, in the event the Company transfers all or substantially all of its rights to a Product to a third party, the Company shall pay to ABSI the percentage of Net Proceeds attributable to the transfer of the Product. Specifically, the Company shall pay ABSI amounts at percentages which range from the mid-single digit to low double digits depending on the Company Expenses (as defined in the ABSI Agreement), with higher Company Expenses being subject to lower rates. On a Product-by-Product basis, upon the expiration of the last Royalty Term of such Product in the Territory, licenses granted to the Company with respect to such Product shall be deemed non-exclusive, fully paid, royalty-free, perpetual and irrevocable. The ABSI Agreement shall expire upon the expiration of the last Royalty Term of the last Product, unless such agreement is terminated earlier pursuant to its terms. The ABSI Agreement may also be terminated (i) by either the Company or ABSI for (A) a material breach of the ABSI Agreement or (B) bankruptcy, (ii) ABSI may terminate the ABSI Agreement upon the commencement of a Challenge Proceeding (as defined in the ABSI Agreement) or (iii) the Company may terminate the ABSI Agreement at any time upon 90 days prior written notice to ABSI. Upon termination or expiration of the ABSI Agreement other than as a result of a bankruptcy or Challenge Proceeding, all licenses granted to the Company pursuant to such agreement will terminate and all rights under such licenses shall revert to ABSI. On March 11, 2024, the Company entered into an addendum to the ABSI Agreement to fund research services with quarterly payments of $50,000 beginning March 18, 2024 with subsequent payments due on the 18th of each calendar quarter. Effective July 31, 2025, the quarterly services agreement was terminated. During the three months ended March 31, 2026 and 2025, the Company incurred research service expense of $<span id="xdx_905_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--AppliedBiomedicalScienceInstituteMember_ziwGlXJqRlzk" title="Payments for research and development">0 and $<span id="xdx_909_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--AppliedBiomedicalScienceInstituteMember_zbaXCn1XYBc" title="Payments for research and development">50,000 to ABSI, respectively. Avior Patent License Agreement On November 3, 2023 (the “Avior Effective Date”), the Company entered into the Avior Patent License Agreement with Avior pursuant to which the Company received an exclusive sublicensable right and license to Licensed Patent Rights and Licensed Technology to, among other things, Develop, have Developed, make, have made, use, sell, import, export and commercialize GV104 and GV103 and to practice the Licensed Technology in connection with the foregoing, throughout the world. Pursuant to the Avior Patent License Agreement, the Company paid Avior an up front license fee of $0.4 million within ten days of the Avior Effective Date and a quarterly license fee of $0.15 million which was paid at the end of each fiscal quarter following the Avior Effective Date. In addition, the Company shall pay Avior a high single digit percentage of any upfront payments received by it as a result of the grant of any sublicenses with respect to GV104. The Company shall also pay Avior milestone payments in the aggregate amount of $27,250,000 upon the occurrence of various development milestones (the “Development Milestone Payments”). Furthermore, the Company shall pay Avior certain fees based upon sales milestones. The payments for such sales milestones range from the low seven digits to the low eight digits with higher sales being subject to higher fees. Finally, the Company shall pay Avior royalties based on net sales. Such royalties range from low single digit percentages to mid-single digit percentages with higher sales being subject to lower percentages. The Avior Patent License Agreement shall expire upon the expiration of the final payment obligation due to Avior as set forth in such agreement. Upon the expiration of the Avior Patent License Agreement, the Company shall have a fully paid, irrevocable, freely transferable and sublicensable worldwide license to the Licensed Patent Rights and Licensed Technology to Develop, have Developed, make, have made, use, have used sell, offer for sale, have sold, import, have imported, export, have exported, commercialize or have commercialized any and all Licensed Products and to practice the Licensed Technology worldwide. Pursuant to the Avior Patent License Agreement, the Company may terminate the agreement at any time without cause, upon 30 days’ prior written notice to Avior along with payment of the next unpaid Development Milestone Payment, if any. Furthermore, either the Company or Avior may terminate the Avior Patent License Agreement (i) on written notice to the other party if the other party materially breaches any provision of the Avior Patent License Agreement and fails to cure such breach within 30 days after the breaching party receives written notice thereof or (ii) on written notice in the event that either party (A) becomes insolvent or admits its inability to pay its debts generally as they become due; (B) becomes subject, voluntarily or involuntarily, to any proceeding under any domestic or foreign bankruptcy or insolvency law, which is not fully dismissed or vacated within 60 days; (C) is dissolved or liquidated or takes any corporate action for such purpose; (D) makes a general assignment for the benefit of creditors; or (E) has a receiver, trustee, custodian or similar agent appointed by order of any court of competent jurisdiction to take charge of or sell any material portion of its property or business. Upon termination of the Avior Patent License Agreement, the license granted pursuant to such agreement shall terminate and all rights in the Licensed Patent Rights and Licensed Products shall revert back to Avior. During the three months ended March 31, 2026 and 2025, the Company incurred milestone fees to Avior of $0 and $200,000, respectively in accordance with the terms of the agreement. Enkefalos License Agreement On June 17, 2024 (the “Enkefalos Effective Date”), the Company signed a letter of intent to enter into the Enkefalos License Agreement with Enkefalos Biosciences Inc. (“Enkefalos”) pursuant to which the Company is licensing the global rights in all fields of use for the products related to the compounds knows as cyclotides to deliver HER2 antibodies across the blood-brain barrier and all associated know-how, technology, intellectual property and related information and constructs, and any associated authorized generic rights and all related assets (collectively, the “Products” referred to in this letter as ENBI-01) from Enkefalos. This agreement was terminated during the six months ended June 30, 2025. Pursuant to the Enkefalos License Agreement, the Company paid Enkefalos an up-front license fee of $150,000, included within research and development expenses, within ten days of the Enkefalos Effective Date. Upon termination of the Enkefalos License Agreement, the license granted pursuant to such agreement terminated and all rights in the Licensed Patent Rights and Licensed Products reverted back to Enkefalos. During the three months ended March 31, 2026 and 2025, the Company incurred license fees of $0 and $200,000, respectively to Enkefalos in accordance with the terms of the agreement. Intract Patent License Agreement On September 11, 2024, the Company entered into the Intract Agreement pursuant to which the Company exclusively licensed INT-023/TH023, an oral anti-Tumor Necrosis Factor-alpha (TNF-α) monoclonal antibody infliximab. Under the terms of the Intract Agreement, the Company licensed global development and commercialization rights (outside of South Korea) to Intract’s Soteria® and Phloral® delivery platform along with an existing supply agreement for infliximab to be used in the oral product development program. Pursuant to the Intract Agreement, the Company paid Intract an up-front license fee of $0.4 million and Intract is eligible to receive additional payments upon an equity financing of the Company and additional payments for future development, regulatory and commercial milestones, as well as mid-single digit royalties based on net product sales. During the six months ended June 30, 2025, the Company amended the Intract Agreement to change the payment terms of certain milestone fees, which increased the total milestone fees by $0.15 million. Pursuant to the Intract Agreement, the Company retains a right of first refusal to continue development and commercialization after a Phase 2 clinical trial. In addition, the Company has the option to exercise the license to Intract’s platform for up to four additional targets. The term of the Intract Agreement expires upon the final payment obligation of Canton Strategic Holdings, Inc. and may be terminated by Canton Strategic Holdings, Inc. at any time upon 90 days written notice to Intract. Either party may terminate the Intract Agreement if the other party materially breaches any provision of the Intract Agreement and fails to cure such breach within 30 days after the breaching party receives written notice thereof. In addition, either party may terminate the Intract Agreement on written notice in the event that either party declare: (a) becomes insolvent or admits inability to pay its debts generally as they become due; (b) becomes subject, voluntarily or involuntarily, to any proceeding under any domestic or foreign bankruptcy or insolvency law, which is not fully dismissed or vacated within 60 days; (c) is dissolved or liquidated or takes any corporate action for such purpose; (d) makes a general assignment for the benefit of creditors; or (e) has a receiver, trustee, custodian or similar agent appointed by order of any court of competent jurisdiction to take charge of or sell any material portion of its property or business. During the three months ended March 31, 2026 and 2025, the Company incurred fees of $0 and $600,000, respectively to Intract in accordance with the terms of the agreement.

150000 1000000 0 0

25107

250000

10000000

8250000

50000

400000 150000

27250000

0 200000 150000 0 200000 400000 150000 0 600000

Note 8 – Related Party Transactions The Company’s Chairman through year ended December 31, 2025 is a partner and licensed broker at President Street Global, a consultant for the Company. His combined ownership, both individually and through President Street Global and additional companies, is approximately <span id="xdx_907_ecustom--InvestmentOwnershipPercentage_iI_pid_dp_uPure_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PresidentStreetGlobalMember_zd0LVsP9VOSi" title="Investment ownership percentage">4% of the Company’s outstanding common stock, including common shares available upon exercise of warrants and vested options to purchase shares of the Company’s common stock. The Company made payments of $800,000 to President Street Global for services rendered during the three months ended March 31, 2026. During the three months ended March 31, 2026, the Company purchased $47,222,299 of CC in OTC transactions from an affiliate cryptocurrency liquidity provider under the control of a shareholder who beneficially owns more than 5% of the Company’s outstanding common stock.

0.04 800000 47222299

Note 9 – Segment Reporting The Company has two reportable segments: digital asset treasury and clinical stage bio-technology. The Company’s Chief Executive Officer serves as the Chief Operating Decision Maker (“CODM”) and evaluates the financial performance of the business and makes resource allocation decisions on the basis of net income/(loss) before income taxes. Summary segment financial performance measures evaluated by the CODM as of March 31, 2026 and December 31, 2025 and for the three months ended March 31, 2026 and 2025: Schedule of Segment Financial Performance <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20260331_zBExDbcXcMh3" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20251231_ztu5zsC54mZa" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Segment Assets</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40E_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--DigitalAssetTreasuryMember_ziKwCxMFstK4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Digital asset treasury segment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">582,999,512</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">513,964,900</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember_zaPzZJkfl3q" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Clinical stage bio-technology segment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,655,101</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,181,535</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Assets_iI_zJkeIcoho1Ji" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">584,654,613</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">519,146,435</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Digital asset treasury segment <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260101__20260331__us-gaap--StatementBusinessSegmentsAxis__custom--DigitalAssetTreasuryMember_zuWZ7ra9NXA3" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250101__20250331__us-gaap--StatementBusinessSegmentsAxis__custom--DigitalAssetTreasuryMember_zBhswgdbDsKi" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended March 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingIncomeLoss_zKbnpC6Ns803" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Loss from operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(35,221,181</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_zFjvpqgvW4Mc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other income (expense) (a)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">318,178</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_zXifRHVDiaH4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Unrealized loss on digital assets holdings</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(15,013,304</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_znzUNMFM0OZj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total loss before income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(49,916,307</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Clinical stage bio-technology segment <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20260101__20260331__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember_znJGemb2w5wk" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20250101__20250331__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember_z5QrI39HN3j3" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended March 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingIncomeLoss_zwcwcpiXIAa9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Loss from operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,647,130</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(2,546,669</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_zyW9mti3LvN3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other income (expense) (a)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,965</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_z5krglAW6hkb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total loss before income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,647,130</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,541,704</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(a)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Other income (expense) consists of interest income and interest expense.</td></tr> </table> The following table is a reconciliation of segment total loss before income taxes to our consolidated total loss before income taxes. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20260101__20260331_z5PcOpITLQx1" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250101__20250331_zM921wl1LjP2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended March 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_hus-gaap--StatementBusinessSegmentsAxis__custom--DigitalAssetTreasuryMember_zp2ijfiZz0zi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Digital asset treasury segment total loss before income taxes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(49,916,307</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember_zYZgjm8bw8R" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Clinical stage bio-technology segment total loss before income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,647,130</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,541,704</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_z8cyEp4UcUG3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Consolidated total loss before income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(51,563,437</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,541,704</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

Summary segment financial performance measures evaluated by the CODM as of March 31, 2026 and December 31, 2025 and for the three months ended March 31, 2026 and 2025: Schedule of Segment Financial Performance <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20260331_zBExDbcXcMh3" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20251231_ztu5zsC54mZa" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Segment Assets</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40E_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--DigitalAssetTreasuryMember_ziKwCxMFstK4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Digital asset treasury segment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">582,999,512</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">513,964,900</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember_zaPzZJkfl3q" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Clinical stage bio-technology segment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,655,101</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,181,535</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Assets_iI_zJkeIcoho1Ji" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">584,654,613</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">519,146,435</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Digital asset treasury segment <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260101__20260331__us-gaap--StatementBusinessSegmentsAxis__custom--DigitalAssetTreasuryMember_zuWZ7ra9NXA3" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250101__20250331__us-gaap--StatementBusinessSegmentsAxis__custom--DigitalAssetTreasuryMember_zBhswgdbDsKi" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended March 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingIncomeLoss_zKbnpC6Ns803" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Loss from operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(35,221,181</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_zFjvpqgvW4Mc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other income (expense) (a)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">318,178</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_zXifRHVDiaH4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Unrealized loss on digital assets holdings</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(15,013,304</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_znzUNMFM0OZj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total loss before income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(49,916,307</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Clinical stage bio-technology segment <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20260101__20260331__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember_znJGemb2w5wk" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20250101__20250331__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember_z5QrI39HN3j3" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended March 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingIncomeLoss_zwcwcpiXIAa9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Loss from operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,647,130</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(2,546,669</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_zyW9mti3LvN3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other income (expense) (a)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,965</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_z5krglAW6hkb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total loss before income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,647,130</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,541,704</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">(a)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Other income (expense) consists of interest income and interest expense.</td></tr> </table> The following table is a reconciliation of segment total loss before income taxes to our consolidated total loss before income taxes. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20260101__20260331_z5PcOpITLQx1" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250101__20250331_zM921wl1LjP2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended March 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_hus-gaap--StatementBusinessSegmentsAxis__custom--DigitalAssetTreasuryMember_zp2ijfiZz0zi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Digital asset treasury segment total loss before income taxes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(49,916,307</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember_zYZgjm8bw8R" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Clinical stage bio-technology segment total loss before income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,647,130</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,541,704</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_z8cyEp4UcUG3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Consolidated total loss before income taxes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(51,563,437</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,541,704</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

582999512

513964900

1655101

5181535

584654613

519146435

-35221181

318178

-15013304

-49916307

-1647130

-2546669

4965

-1647130

-2541704

-49916307

-1647130

-2541704

-51563437

-2541704

Note 10 – Subsequent Events Except as noted below, there were no material subsequent events that required recognition or additional disclosure in these consolidated financial statements. ATM Sales From April 1, 2026 to May 11, 2026 the Company has sold <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260401__20260511__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFiveATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDppnPdLwqRf" title="Number of shares sold">936,609 shares of common stock pursuant to the 2025 ATM Agreement and March 2026 ATM Agreement for net proceeds of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn4n6_c20260401__20260511__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFiveATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZj04mdpqPng" title="Proceeds from sale of stock">3.26 million after deducting commissions of approximately $<span id="xdx_90F_eus-gaap--ProceedsFromCommissionsReceived_pn3n3_c20260401__20260511__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFiveATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8LyRlX8GAUg" title="Commissions fees">50 thousand.

936609

3260000

50000

false false false false The exercise and expiration dates for the referenced common warrants were amended in October 2025 to reflect an exercise date of October 1, 2025. Other income (expense) consists of interest income and interest expense.